ArticleEJHaem2026
Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasma cell leukemia and central nervous system involvement are two poor prognostic factors in myeloma, and such patients are often excluded from clinical trials. Case: A 59-year-old patient with primary plasma cell leukemia developed leptomeningeal CNS disease following autologous transplant. Intrathecal chemotherapy and selinexor, pomalidomide, and dexamethasone failed to clear cerebrospinal fluid plasma cells. Intervention: Elranatamab achieved complete serological and CNS response. The patient recovered from bedbound status to full independence and proceeded to receive CAR-T therapy. At 8 months post CAR-T, he remains in sustained MRD negativity. Conclusion: Sequential bispecific antibody and CAR-T therapy demonstrates exceptional efficacy in CNS multiple myeloma, offering new hope for this historically terminal condition and supporting the systematic study of novel immunotherapies in high-risk myeloma populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.